uploads/2018/03/TAF.png

How Gilead Sciences’ TAF-Containing HIV Drugs Performed

By

Updated

Genvoya revenue trends

In 4Q17, Gilead Sciences’ (GILD) Genvoya generated revenues of $1.1 billion, which reflected ~88% growth on a year-over-year (or YoY) basis and 7% growth quarter-over-quarter. In 4Q17, in the US, Europe, and other international markets, Genvoya generated revenues of $844 million, $176 million, and $40 million, respectively, compared to $485 million, $68 million, and $10 million, respectively.

In fiscal 2017, Genvoya generated revenues of $3.7 billion compared to $1.5 billion in 2016. In 2017, in the US, Europe, and other international markets, Genvoya reported revenues of $3.0 billion, $534 million, and $107 million, respectively, compared to $1.3 billion, $160 million, and $23 million, respectively.

Article continues below advertisement

Odefsey revenue trends

In 4Q17, Odefsey saw revenues of $325 million compared to $155 million in 4Q16. In 4Q17, Odefsey witnessed ~10% growth on a quarter-over-quarter basis. In 4Q17, in the US and Europe, Odefsey generated revenues of $276 million and $45 million, respectively, compared to $138 million and $17 million in 4Q16.

In fiscal 2017, Odefsey reported revenues of $1.1 billion compared to $329 million in 2016. In 2017 in the US, Europe, and other international markets, Odefsey generated revenues of $964 million, $132 million, and $10 million, respectively.

Descovy’s revenue trends

In 4Q17, Descovy generated revenues of $365 million compared to $149 million in 4Q16. In 4Q17, Descovy witnessed ~16% growth on a quarter-over-quarter basis. In 4Q17, in the US, Europe, and other international markets, Descovy reported revenues of $276 million, $77 million, and $12 million, respectively, compared to $112 million, $34 million, and $3 million in 4Q16.

In fiscal 2017, Descovy generated revenues of $1.2 billion compared to $298 million in 2016. In 2017, in the US, Europe, and other international markets, Descovy generated revenues of $958 million, $226 million, and $34 million, respectively, compared to $226 million, $69 million, and $3 million in 2016.

In the anti-HIV drugs market, Gilead Sciences’ anti-HIV drugs compete with Trizivir and Epzicom, both of which were commercialized by ViiV Healthcare, a joint venture between Pfizer (PFE) and GlaxoSmithKline (GSK) for the development of anti-HIV drugs and Johnson & Johnson’s (JNJ) Prezcobix.

Advertisement

More From Market Realist